HRTX vs JAZZ vs SUPN vs PCRX vs PRGO

For growth investors, Supernus Pharmaceuticals, Inc.

(SUPN) is the stronger pick with 8. 6% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Pacira BioSciences, Inc. (PCRX) offers the better valuation at 144. 7x trailing P/E (8. 1x forward), making it the more compelling value choice. Analysts rate Heron Therapeutics, Inc. (HRTX) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Perrigo Company plc is actually cheaper at 5.

5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Supernus Pharmaceuticals, Inc.

(SUPN) delivered a total return of +75. 6%, compared to -93. 1% for Heron Therapeutics, Inc. (HRTX). Over 10 years, the gap is even starker: SUPN returned +223. 7% versus HRTX's -93. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pacira BioSciences, Inc.

(PCRX) is the lower-risk stock at 0. 41β versus Heron Therapeutics, Inc. 's 1. 81β — meaning HRTX is approximately 338% more volatile than PCRX relative to the S&P 500. On balance sheet safety, Supernus Pharmaceuticals, Inc. (SUPN) carries a lower debt/equity ratio of 4% versus 10% for Heron Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Supernus Pharmaceuticals, Inc.

(SUPN) is pulling ahead at 8. 6% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Pacira BioSciences, Inc. grew EPS 107. 4% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, HRTX leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pacira BioSciences, Inc.

(PCRX) is the more profitable company, earning 1. 0% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 1. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -5. 1% for SUPN. At the gross margin level — before operating expenses — SUPN leads at 89. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 20. 8x for Supernus Pharmaceuticals, Inc. — 15. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HRTX: 451. 2% to $6. 67.

In this comparison, PRGO (9.

8% yield) pays a dividend. HRTX, JAZZ, SUPN, PCRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pacira BioSciences, Inc.

(PCRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41)). Heron Therapeutics, Inc. (HRTX) carries a higher beta of 1. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PCRX: -52. 2%, HRTX: -93. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HRTX is a small-cap quality compounder stock; JAZZ is a mid-cap quality compounder stock; SUPN is a small-cap quality compounder stock; PCRX is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while HRTX, JAZZ, SUPN, PCRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.